- Home
- UPB vs ADGM Comparison
UPB vs ADGM Comparison
Compare UPB & ADGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPB
- ADGM
- Stock Information
- Founded
- UPB 2021
- ADGM 2011
- Country
- UPB United States
- ADGM United States
- Employees
- UPB N/A
- ADGM N/A
- Industry
- UPB
- ADGM
- Sector
- UPB
- ADGM
- Exchange
- UPB NYSE
- ADGM NYSE
- Market Cap
- UPB 1.0B
- ADGM 33.4M
- IPO Year
- UPB 2024
- ADGM N/A
- Fundamental
- Price
- UPB $16.30
- ADGM $1.17
- Analyst Decision
- UPB Strong Buy
- ADGM
- Analyst Count
- UPB 4
- ADGM 0
- Target Price
- UPB $56.50
- ADGM N/A
- AVG Volume (30 Days)
- UPB 460.2K
- ADGM 1.0M
- Earning Date
- UPB 02-14-2025
- ADGM 02-15-2025
- Dividend Yield
- UPB N/A
- ADGM N/A
- EPS Growth
- UPB N/A
- ADGM N/A
- EPS
- UPB N/A
- ADGM N/A
- Revenue
- UPB $2,207,000.00
- ADGM $543,000.00
- Revenue This Year
- UPB N/A
- ADGM N/A
- Revenue Next Year
- UPB N/A
- ADGM N/A
- P/E Ratio
- UPB N/A
- ADGM N/A
- Revenue Growth
- UPB 82.10
- ADGM 187.30
- 52 Week Low
- UPB $14.97
- ADGM $0.95
- 52 Week High
- UPB $29.46
- ADGM $9.34
- Technical
- Relative Strength Index (RSI)
- UPB N/A
- ADGM N/A
- Support Level
- UPB N/A
- ADGM N/A
- Resistance Level
- UPB N/A
- ADGM N/A
- Average True Range (ATR)
- UPB 0.00
- ADGM 0.00
- MACD
- UPB 0.00
- ADGM 0.00
- Stochastic Oscillator
- UPB 0.00
- ADGM 0.00
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for treatment of cardiac arrhythmias. The company focuses on developing innovative cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.